23 results about "Pet tracer" patented technology

The invention discloses a compound targeting AT1R, which is composed of a target head molecule targeting AT1R, a PEG linker, an aspartic acid linker and a chelating agent, and can be used as a component of a PET tracer agent targeting AT1R. A target head molecule can be embedded into a hydrophobic'pocket 'of AT1R protein, so that high-affinity and high-selectivity targeted binding is realized; the PEG connexon can prolong the residence time of the PET tracer agent targeting the AT1R at the tumor part; different numbers of aspartic acids can regulate and control the pharmacokinetic properties of the PET tracer agent targeting the AT1R, reduce the liver and gall and intestinal signal backgrounds of the PET tracer agent targeting the AT1R, and improve the target-to-cost ratio. Therefore, accurate diagnosis and treatment of digestive system diseases such as digestive tract tumor and liver cancer can be realized. The invention further discloses a PET tracer agent targeting AT1R as well as a preparation method and application of the PET tracer agent.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.

A system and method for simultaneous imaging of multiple positron emission tomography (PET) tracers in which digital data including PET information associated with at least two time points is received, where the digital data is generated by PET scans of a region of interest of a physiologic body which has been administered at least two PET tracers that differ from one another at least in their radioactive decay constant. At least one set of output digital data is determined based on the radioactive decay constants of each PET tracer, the at least one set of output digital data corresponding to at least one of the at least two PET tracers. The determination of at least one set of output digital data includes at least one of regularizing to account for statistical noise, preconditioning the digital data to be more amenable to signal separation, applying feature preservation techniques, or accounting for late tracer kinetics.

A radiosynthesis system is disclosed that leverages droplet microfluidic radiosynthesis and its inherent advantages including reduction of reagent consumption and the ability to achieve high molar activity even when using low starting radioactivity. The radiosynthesis system enables the parallel synthesis of radiolabeled compounds using droplet-sized reaction volumes. In some embodiments, a single heater is used to create multiple reaction or synthesis sites. In other embodiments, separate heaters are used to create independently-controlled heating conditions at the multiple reaction or synthesis sites. In one embodiment, a four-heater setup was developed that utilizes a multi-reaction microfluidic chip and was assessed for the suitability with high-throughput radiosynthesis optimization. Replicates of several radiochemical operations including the full synthesis of various PET tracers revealed the platform to have high repeatability (e.g., consistent fluorination efficiency). The system may also be used for synthesis optimization.

Recombinant proteins that specifically bind TGFβ are disclosed. The recombinant proteins include a transforming growth factor beta (TGFβ) binding domain and an antibody Fc fragment. Also disclosed are compositions that include the disclosed recombinant protein, and methods of using such compositions for detecting TGFβ in a subject.

The invention provides a novel PET (Polyethylene Terephthalate) tracer agent of a targeted cannabinoid type 2 receptor and a preparation method of the novel PET tracer agent.

Disclosed herein is a PET tracer compound (S)-1-(2-(6-[18F]fluoropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide and salts thereof, and uses of the same as imaging agents. Also disclosed are precursor compounds, such as (S)-1-(2-(6-nitropyridin-3-yl)-4-(trifluoromethyl)phenyl)-N-(pyrimidin-2-yl)-2,3-dihydro-1H-indene-5-sulfonamide, and salts thereof. Also disclosed are kits comprising the same.

The present application provides a radiolabeled compound targeting cannabinoid receptor type 1 with radionuclide 18F. The present application also provides a method for preparing the compound and its use as a positron emission tomography (PET) imaging agent.

The application discloses a PET tracer targeting carbonic anhydrase IX (CA IX) and a preparation method and application thereof. 68 The tracer is prepared from a DOTA-bis-sulfonamide precursor compound and GaCl3 reaction. The tracer has high hydrophilicity, excellent stability in vitro and in vivo, low uptake of non-target organs and is mainly excreted through the kidney. Micro-PET / CT imaging shows that the tumor uptake is linearly correlated with the CA IX protein expression level measured by immunohistochemistry. Acute toxicity experiments show that the tracer has good biological safety. The application further provides a radiopharmaceutical composition containing the tracer and application of the tracer in preparation of a PET imaging agent for diagnosing CA IX positive tumors. The tracer has the advantages of high labeling efficiency, low background interference, accurate quantification and potential integration of diagnosis and treatment, and is suitable for precise molecular imaging of CA IX high expression tumors such as clear cell renal cell carcinoma and colorectal cancer.

There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

The present application provides a PET tracer targeting cannabinoid receptor type 2 and a preparation method and application thereof.

The present invention relates to a device that allows to fully automate radiochemical purity analysis of radiolabelled solution samples on the basis of a chromatogram obtained by Thin Layer Chromatography (TLC), said device comprising a disposable TLC strip holder assembly, a radioactivity detector and an automatic equipment containing a pipettor.

The present invention relates to a device that allows for fully automated radiochemical purity analysis of radiolabeled solution samples based on chromatograms obtained by thin layer chromatography (TLC), said device comprising a disposable TLC strip holder assembly, a radioactivity detector and an automated device containing a pipettor.

There is provided two angiogenesis clinical PET tracers, namely 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2 for imaging of neo-angiogenesis in humans.

The present invention relates to new and inventive compounds of formula (I). The compounds are useful as PET (positron emission tomography) tracer.

The application belongs to the technical field of biological medicine, and particularly relates to design, synthesis and application of a tumor-targeting polypeptide tracer. The structure of the tumor-targeting polypeptide tracer comprises a tumor-targeting polypeptide (targeting vascular endothelial growth factor receptor 2 of tumor cells), a linker and a radionuclide chelating group. The polypeptide tracer provided by the application is modified by methionine at different sites to form a thioether bridge cyclic peptide, so that the tumor targeting ability, membrane penetration performance and in-vivo drug metabolism of the targeting polypeptide are improved, high concentration enrichment and long-time retention in the tumor tissue site can be realized, the targeting of the PET tracer is improved, and a more accurate and safer tumor tracer is realized.

The invention discloses a PET (Polyethylene Terephthalate) tracer targeting mGluR5. The PET tracer comprises a pyridine ring and a substituted benzene ring, a No.1 carbon atom of the substituted benzene ring is connected with a No.6 carbon atom of the pyridine ring through ethynyl, a No.2 carbon atom of the pyridine ring is connected with-CH3, and a No.3 carbon atom on the substituted benzene ring is connected with-OSO218F; substituent groups R1 are connected to a No.1 nitrogen atom, a No.3 carbon atom, a No.4 carbon atom and a No.5 carbon atom of a pyridine ring, substituent groups R2 are connected to a No.2 carbon atom, a No.4 carbon atom, a No.5 carbon atom and a No.6 carbon atom of a substituted benzene ring, and R1 is selected from a hydrogen atom, a cyano group, a halogen atom, a short-chain alkyl group, a short-chain alkoxy group, a hydroxyl group and a hydroxymethyl group; r2 is selected from a hydrogen atom, a cyano group, a halogen atom, a short-chain alkyl group and a short-chain alkoxy group. The PET tracer agent targeting mGluR5 provided by the invention has high specific binding capacity, and can realize accurate positioning and quantitative analysis of mGluR5 in a living body. The invention further discloses a preparation method and application of the PET tracer agent targeting mGluR5.

Two angiogenic clinical PET tracers, 68Ga-NODAGA-E[c(RGDyK)]2 and 64Cu-NODAGA-E[c(RGDyK)]2, are presented for imaging neovascularization in humans.

Disclosed herein is a PET tracer compound N-cyclopropyl-1-(4-(4-(fluoro-18F) phenyl)pyrimidin-5-yl)-N-methyl piperidine-4-carboxamide or salt thereof, and uses as an imaging agent. In certain embodiments, this disclosure relates to precursor compounds such as N-cyclopropyl-N-methyl-1-(4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) phenyl)pyramidin-5-yl)piperidine-4-carboxamide or salt thereof and kits comprising the same.

This invention relates to the field of tracer preparation technology, and specifically discloses a method for preparing a positron emission tomography (PET) tracer that penetrates the blood-brain barrier and targets hypoxia-inducible factor (HIF). The tracer is a compound with HIF targeting and rapid brain tumor enrichment capabilities, and comprises the following parts: a) a short-half-life radionuclide portion for PET imaging; b) a HIF-1α protein-binding domain; and c) a lipophilic linker / regulatory domain for modulating intracranial pharmacokinetics. This method for preparing a PET tracer that penetrates the blood-brain barrier and targets HIF integrates high-affinity targeting and tumor microenvironment response mechanisms, giving it excellent targeting specificity, rapid brain penetration and enrichment capabilities, and ideal rapid systemic clearance characteristics, thereby obtaining high-contrast, low-background, high-quality images.

A system and method for simultaneous imaging of multiple positron emission tomography (PET) tracers in which digital data including PET information associated with at least two time points is received, where the digital data is generated by PET scans of a region of interest of a physiologic body which has been administered at least two PET tracers that differ from one another at least in their radioactive decay constant. At least one set of output digital data is determined based on the radioactive decay constants of each PET tracer, the at least one set of output digital data corresponding to at least one of the at least two PET tracers. The determination of at least one set of output digital data includes at least one of regularizing to account for statistical noise, preconditioning the digital data to be more amenable to signal separation, applying feature preservation techniques, or accounting for late tracer kinetics.

The invention discloses an aging cell targeting PET imaging tracer agent capable of penetrating a blood brain barrier as well as a preparation method and application of the aging cell targeting PET imaging tracer agent. The PET tracer is 18F-QM-beta-gal, the chemical name of the PET tracer is 2-(1-(2-([18] fluorine) ethyl)-2-((E)-4-(((2S, 3R, 4S, 5R, 6R)-3, 4, 5-trihydroxy-6-(hydroxymethyl) tetrahydro-2H-pyran-2-yl) oxy) styryl) quinoline-4 (1H)-subunit) malononitrile, the radiochemical purity and stability of the PET tracer can be effectively improved by optimizing the preparation method of the PET tracer, and the detection effect of the PET tracer is guaranteed. The tracer has blood brain barrier penetrability, and the compound can be applied to senescence level detection of brain tissues in natural and disease states, such as senescence cell quantification in old brain tissues and old Alzheimer disease brain tissues. The invention provides the novel PET tracer agent which can penetrate through the blood brain barrier, is high in specificity and biological safety and is used for in-vivo visualization of the senescent cells in the brain for the first time, and a brand-new method is provided for evaluating senescence of the cells in the brain.

The invention relates to the technical field of radioactive polypeptide pharmaceutical chemistry, discloses a tumor PD-L1 targeting PET tracer and a labeled precursor, a preparation method and application thereof, and belongs to the technical field of radioactive polypeptide pharmaceutical chemistry. The PEG tracer is of an F-X-R-G structure, X is a chelating agent, R is a connecting arm, G is a polypeptide compound, the amino acid sequence of the polypeptide compound is NYSKPTDRQYHF, and F is selected from 68Ga. Experimental verification shows that the prepared PET tracer has good in-vivo stability, good tumor PD-L1 binding specificity, long tumor residence time and easiness in synthesis. The PET tracer prepared by the invention has an important value in clinical application in polypeptide targeted nuclear drug tumor diagnosis and treatment integration.